Kim Jae Heon, Lee Sang Wook, Kim Jae Ho, Yang Hee Jo, Doo Seung Whan, Yoon Jong Hyun, Kim Doo Sang, Yang Won Jae, Lee Kwang Woo, Kim Jun Mo, Lee Changho, Kwon Soon-Sun
Department of Urology, College of Medicine, Soonchunhyang University, Cheonan, Korea.
Department of Urology, College of Medicine, Soonchunhyang University, Cheonan, Korea
J Int Med Res. 2014 Jun;42(3):821-7. doi: 10.1177/0300060513518038. Epub 2014 Apr 17.
To determine the association between body mass index (BMI), serum prostate-specific antigen (PSA) level and PSA density (PSAD) in patients with an elevated serum PSA level but a negative prostate biopsy.
This retrospective study enrolled men with a negative prostate biopsy but a serum PSA level of 3.0-10 ng/ml. All men underwent anthropometric measurements, serum PSA determination and transrectal ultrasound examination. BMI was grouped according to the Asia-Pacific obesity criteria: nonobese (<25 kg/m(2)) versus obese (≥ 25 kg/m(2)). Partial correlation and linear regression models between PSA, PSAD and BMI were conducted after adjusting for age.
A total of 907 men were enrolled in this study. On multivariate analyses, PSA showed no significant correlation with age or BMI, whereas PSAD had a negative correlation with age and BMI. Similar results were obtained when patients were categorized as having low (3.0 < PSA ≤ 6.5 ng/ml) or high PSA (6.5 < PSA ≤ 10.0 ng/ml) levels.
PSAD, but not PSA, demonstrated a significant negative correlation with BMI. This indicates that a new strategy including PSAD rather than simple PSA levels should be adopted in the study of obesity-adjusted PSA cut-offs.
确定血清前列腺特异性抗原(PSA)水平升高但前列腺活检结果为阴性的患者中,体重指数(BMI)、血清PSA水平与PSA密度(PSAD)之间的关联。
这项回顾性研究纳入了前列腺活检结果为阴性但血清PSA水平为3.0 - 10 ng/ml的男性。所有男性均接受了人体测量、血清PSA测定及经直肠超声检查。BMI根据亚太地区肥胖标准进行分组:非肥胖(<25 kg/m²)与肥胖(≥25 kg/m²)。在对年龄进行校正后,对PSA、PSAD和BMI之间进行偏相关和线性回归分析。
本研究共纳入907名男性。多因素分析显示,PSA与年龄或BMI无显著相关性,而PSAD与年龄和BMI呈负相关。当将患者分为低PSA水平(3.0 < PSA ≤ 6.5 ng/ml)或高PSA水平(6.5 < PSA ≤ 10.0 ng/ml)时,也得到了类似结果。
PSAD与BMI呈显著负相关,而PSA与BMI无显著相关性。这表明在研究肥胖校正的PSA临界值时,应采用包括PSAD而非简单PSA水平的新策略。